<DOC>
	<DOCNO>NCT01570686</DOCNO>
	<brief_summary>The purpose study evaluate effect food aliskiren 's efficacy , pharmacokinetics safety follow oral dose 300 mg , give daily light meal versus fast condition .</brief_summary>
	<brief_title>8-week Randomized , Open-label Study Evaluate Food Effect Efficacy Safety Oral Aliskiren 300 mg Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Patients essential hypertension , untreated currently take antihypertensive therapy ( monotherapy combination therapy ) . Patients office BP ≥ 140/90 mmHg &lt; 180/110mmHg randomization visit precede visit Patients must absolute difference ≤ 10 mmHg msSBP msDBP randomization visit precede visit Malignant hypertension severe hypertension ( grade 3 WHO classification ; msSBP ≥180 mmHg msDBP ≥110 mmHg ) History evidence secondary form hypertension , renal parenchymal hypertension , renovascular hypertension , coarctation aorta , primary hyperaldosteronism , Cushing 's disease , druginduced hypertension , unilateral bilateral renal artery stenosis , pheochromocytoma , polycystic kidney disease ( PKD ) . Type 1 Type 2 diabetes mellitus fast glycosylated hemoglobin ( HbA1c ) &gt; 8 % Evidence renal impairment determine one following : serum creatinine &gt; 1.5 x ULN eGFR &lt; 30 ml/min/1.73m2 Visit 1 , history dialysis , history nephrotic syndrome Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Food effect , hypertension , aliskiren</keyword>
</DOC>